Meta Pixel

News and Announcements

Material gains: Swinburne spin-out EntroMat takes aim at $160b global market

  • Published June 24, 2026 3:43AM UTC
  • Publisher Jade Miguel
  • Categories Capital Insights, Executive Interviews, Landing, Trending

Traditional metallurgy has hit a wall, and Melbourne-based deep-tech startup EntroMat believes the answer lies in the trillions of atomic combinations it is unlocking via physics-based artificial intelligence.

Speaking on the sidelines of the Emergence 2026 flagship conference in Sydney, EntroMat chief executive Greg Lindsay revealed the company is on the cusp of commercial scaling, with eyes firmly set on disrupting the $9 billion global metal powder market and the broader $160 billion advanced materials sector.

A spin-out from Swinburne University of Technology, EntroMat is pioneering the development of high-entropy materials—next-generation alloys engineered to withstand the brutal operational environments that push conventional metals to catastrophic failure.

YouTube player

Decoding the complexity of “high-entropy”

For decades, industrial sectors like mining, aerospace, and energy have managed a delicate balance with component wear and tear. Traditional alloys fail under extreme heat, pressure, acidity, or particle erosion, costing operators millions in downtime and lost productivity.

EntroMat’s solution sidesteps traditional metallurgy by mixing five or more elements in equiatomic (equal) proportions.

“The challenge there is that you need to computationally predict [the outcomes] because there are trillions of combinations when you take into account the periodic table,” Lindsay explained.

To solve this, the company is commercialising predictive computational capabilities developed at Swinburne, accelerated by what Lindsay terms “physical AI.”

“This is not just AI where you throw it over the fence and somebody else manufactures it. We are actually going to manufacture the materials. We have lab-scale capability right now… we validate the results we achieve and feed that back into the AI. It’s science-based engineering knowledge driving the system.”

The green premium without the cost

Crucially for institutional investors eye-ing ESG mandates, EntroMat’s business model does not rely on virgin critical minerals. Instead, the company is building a circular feedstock loop.

“Where we need nickel, we won’t buy pure nickel,” Lindsay said. “We’ll buy scrap Inconel material—which is very high in nickel—and use other recycled materials. We want to reduce the demand on critical minerals.”

This circular approach has already yielded commercial interest in Europe. EntroMat is currently developing bespoke material solutions designed to bypass strict European REACH environmental regulations, offering continental heavy-industry players a compliant, highly durable alternative to hazardous legacy coatings.

The commercial runway

EntroMat is approaching a sharp technical-to-commercial inflection point. While the long-term horizon includes high-margin medtech applications like biocompatible, rejection-resistant implants, the immediate revenue thesis is anchored in heavy industry.

The company is currently running proof-of-concept projects across:

  • Australia: Partnering with the local tier-one mining sector to combat asset erosion.
  • North America & Europe: Deploying field tests for extreme industrial applications.

The financial runway is heavily non-dilutive. Swinburne University was recently awarded an Australian Government grant with EntroMat as the exclusive industry partner, effectively creating a three-times R&D multiplier. “We put in $1 million, we get $3 million worth of R&D,” Lindsay noted.

Investor outlook

The timeline for investors is compressed. EntroMat expects to install and commission commercial-scale manufacturing equipment by early 2027.

With commercial contracts expected to land in the second half of this year, the company expects a rapid transition into full commercial supply by 2027.

“We are quite small currently, but we have the customers right now, we have access to the equipment, and we have large-scale R&D activity in place,” Lindsay said. “We have a very fast path to growth right in front of us.”

Capital Insights
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula

Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.

Join over 45,000+ sophisticated investors

Join Now